Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

degarelix

- PMLiVE

ICR researchers uncover genes responsible for tumour progression in prostate cancer

The findings could pave the way for new treatment approaches that improve patient outcomes

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE to treat advanced breast cancer

BRCA1 and BRCA2 mutations are responsible for 52% and 32% of hereditary breast cancer cases, respectively

- PMLiVE

Prostate cancer blood test with ‘unprecedented accuracy’ cuts biopsies by 50%

There is currently no national screening programme for prostate cancer in the UK

- PMLiVE

NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

- PMLiVE

GSK and Rgenta to develop RNA-targeting small molecules in deal worth up to $500m per target

The alliance is aimed at advancing treatments for multiple disease areas, including oncology

- PMLiVE

ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

The research could pave the way for the development of new drugs that prevent drug resistance

- PMLiVE

NICE recommends Immunocore’s Kimmtrak as first drug for aggressive eye cancer

More than 100 patients are expected to be eligible for the treatment every year

- PMLiVE

AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study

More than 52,000 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

Merck gains rights to LaNova’s PD-1/VEGF bispecific antibody in deal worth over $3.2bn

A phase 1 clinical trial of the candidate in advanced solid tumours is currently enrolling patients

- PMLiVE

Roche and Flare Therapeutics enter oncology partnership worth over $1.8bn

The companies will aim to discover small molecule treatments aimed at previously undrugged transcription factor targets

Daiichi Sankyo logo

Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu

The company will use Alteogen’s hybrozyme technology to advance the formulation

- PMLiVE

NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder

Systemic mastocytosis affects approximately one in every 10,000 people in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links